Q3 2023 Results
Company overview
Financial review
Conclusions
Appendix
References
Raising FY guidance for core operating income
Expected, barring unforeseen events; growth vs. PY in cc
Novartis (Continuing operations¹)
Net sales expected to grow
high single digit
Core operating income expected
to grow mid to high teens
Unchanged from previous guidance
Raised from low double digit to mid-teens
Key assumptions
■ No US Entresto® Gx at risk launch in 2023
■ No SandostatinⓇ LAR generics enter in the US in 2023
FINANCIAL PROFILE
1. As defined on page 37 of the Condensed Interim Financial Report, Continuing operations include the retained business activities of Novartis, comprising the Innovative Medicines Division and the continuing Corporate activities. Core results
and constant currencies are non-IFRS measures. Further details regarding non-IFRS measures can be found starting on page 48 of the Condensed Interim Financial Report.
26 Investor Relations | Q3 2023 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation